Dyslipidemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

GlobalData, September 2011, Pages: 112

Dyslipidemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Dyslipidemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Dyslipidemia Therapeutics market. The report identifies the key trends shaping and driving the global Dyslipidemia Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Dyslipidemia Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Dyslipidemia Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Dyslipidemia Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Dyslipidemia Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Dyslipidemia Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Dyslipidemia Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Dyslipidemia Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Dyslipidemia Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Dyslipidemia Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of contents
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 Dyslipidemia Therapeutics - Introduction
2.1 Overview
2.1.1 Lipids and Lipoproteins
2.1.2 Types of Lipoproteins
2.1.3 Lipid Generation and Transportation
2.2 Pathophysiology
2.3 Epidemiology
2.3.1 Prevalence
2.4 Etiology
2.4.1 Types of Dyslipidemia
2.5 Symptoms
2.5.1 Xanthelasma
2.5.2 Xanthoma tendinosum
2.5.3 Palmer xanthoma
2.6 Diagnosis
2.6.1 Lipid Profiling
2.6.2 Ultracentrifugation Method
2.6.3 Immunoassay method
2.6.4 Lp (a) Level Measurement
2.6.5 Test for the Determination of Secondary Causes of Dyslipidemia
2.6.6 Screening
2.6.7 Diagnosis Pathway of Dyslipidemia
2.7 Treatment and Management Pattern
2.7.1 Therapeutic Life Style Changes (TLC)
2.7.2 Drug Therapy
2.7.3 Combination Therapy
2.7.4 Estrogen Replacement Therapy
2.7.5 Gene Therapy
2.7.6 Plasmapheresis
2.7.7 Surgical Modalities
2.8 Report Guidance
3 Dyslipidemia Therapeutics - Market Characterization
3.1 Dyslipidemia Therapeutics Market Size (2005–2010) – Global
3.2 Dyslipidemia Therapeutics Market Forecast (2010–2018) – Global
3.3 Dyslipidemia Therapeutics Market – The US (2005–2010)
3.4 Dyslipidemia Therapeutics Market Forecast – The US (2010–2018)
3.5 Dyslipidemia Therapeutics Market – France (2005–2010)
3.6 Dyslipidemia Therapeutics Market Forecast – France (2010–2018)
3.7 Dyslipidemia Therapeutics Market – Germany (2005–2010)
3.8 Dyslipidemia Therapeutics Market Forecast - Germany (2010–2018)
3.9 Dyslipidemia Therapeutics Market – Italy (2005–2010)
3.10 Dyslipidemia Therapeutics Market Forecast – Italy (2010–2018)
3.11 Dyslipidemia Therapeutics Market – Spain (2005–2010)
3.12 Dyslipidemia Therapeutics Market Forecast – Spain (2010–2018)
3.13 Dyslipidemia Therapeutics Market – The UK (2005–2010)
3.14 Dyslipidemia Therapeutics Market Forecast –The UK (2010–2018)
3.15 Dyslipidemia Therapeutics Market - Japan (2005–2010)
3.16 Dyslipidemia Therapeutics Market Forecast – Japan (2010–2018)
3.17 Drivers and Barriers for the Dyslipidemia Therpeutics Market
3.17.1 Dyslipidemia Therapeutics Market Drivers
3.17.2 Dyslipidemia Therapeutics Market Barriers
3.18 Opportunity and Unmet Need
3.19 Key Takeaway
4 Dyslipidemia Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for Major Marketed Products in the Dyslipidemia
4.3.1 Lipitor (atorvastatin calcium)
4.3.2 Vytorin (ezetimibe/simvastatin)
4.3.3 Zetia (ezitimibe)
4.3.4 Tricor (fenofibrate)
4.3.5 Crestor (rosuvastatin calcium)
4.3.6 Lescol (fluvastatin sodium)
4.3.7 Simcor (simvastatin/niacin extended release)
4.3.8 Livalo (pitavastatin calcium)
4.3.9 Lovaza (omega-3-acid ethyl esters)
4.3.10 Niaspan (nicotinic acid)
4.3.11 Trilipix (fenofibric acid)
4.4 Key Takeaway
5 Dyslipidemia Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Dyslipidemia Therapeutics Market – Pipeline Assessment by Phase of Development
5.3.1 Dyslipidemia – Phase III Pipeline
5.3.2 Dyslipidemia – Phase II Pipeline
5.3.3 Dyslipidemia – Phase I Pipeline
5.3.4 Dyslipidemia – Preclinical Pipeline
5.3.5 Dyslipidemia – Discovery Pipeline
5.4 Dyslipidemia Therapeutics – Pipeline by Mechanism of Action
5.5 Technology Trends Analytical Framework
5.6 Dyslipidemia Therapeutics Market – Most Promising Drugs Under Clinical Development
5.7 Most Promising Drug Profiles
5.7.1 Anacetrapib (MK- 0859)
5.7.2 AMR 101
5.7.3 Darapladib
5.7.4 Dalcetrapib (RG1658)
5.7.5 DCCR
5.7.6 Lomitapide
5.7.7 Mipomersen
5.7.8 Varespladib (A-002)
5.7.9 MK- 0524B
5.7.10 Tredaptive (MK-0524A)
5.7.11 Glybera (AMT-011)
5.7.12 Aleglitazar (RG1439)
5.7.13 ZYH1
5.8 Key Takeaway
6 Dyslipidemia Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (US, EU-5 and Japan)
6.2 Clinical Trials by Phase of Clinical Development
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Brief Profiles of Top Ten Companies Participating in Therapeutics Clinical Trials
7 Dyslipidemia Therapeutics - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario
8 Dyslipidemia Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 GlaxoSmithKline Plc
8.2.2 Merck & Co., Inc.
8.2.3 F. Hoffmann-La Roche
8.2.4 ISIS Pharmaceuticals
8.2.5 Anthera Pharmaceuticals
8.2.6 Amarin Corporation plc.
8.2.7 Essentialis, Inc
8.2.8 Aegerion Pharmaceuticals
8.2.9 Tabular Presentation Details of Other Companies in the Pipeline
8.2.10 Key Takeaway
9 Dyslipidemia Therapeutics - Licensing & Partnership Deals
10 Dyslipidemia Therapeutics - Appendix
10.1 Definitions
10.2 Acronyms
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Dyslipidemia Therapeutics, Global, Lipoprotein Patterns and Fredrickson Classification
Table 2: Dyslipidemia Therapeutics, Global, Secondary Causes of Lipoprotein Abnormalities
Table 3: Dyslipidemia Therapeutics, Global, Coronary Heart Disease Risk Based on Risk Factors Other than LDL
Table 4: Dyslipidemia Therapeutics, Global, Major Causes of Secondary Dyslipidemia
Table 5: Dyslipidemia Therapeutics, Global, NCEP ATP III Classification of Cholesterol and Triglyceride Levels
Table 6: Dyslipidemia Therapeutics, Global, ATP III LDL-C Goals and Outpoints for Therapeutics Lifestyle Changes and Drug Therapy in Different Risk Categories
Table 7: Dyslipidemia Therapeutics, Global, Full Fasting Lipid Profiling
Table 8: Dyslipidemia Therapeutics, Global, Steps in Dyslipidemia Diagnosis
Table 9: Dyslipidemia Therapeutics, Global, Drugs Used for Lipoprotein Disorder
Table 10: Dyslipidemia Therapeutics Market, Global, Revenue ($bn), 2005–2010
Table 11: Dyslipidemia Therapeutics, Major Market, Global, Forecast ($bn), 2010–2018
Table 12: Dyslipidemia Therapeutics Market, The US, Revenue ($bn), 2005–2010
Table 13: Dyslipidemia Therapeutics, Major Market, US, Forecast ($bn), 2010–2018
Table 14: Dyslipidemia Therapeutics, France, Revenue ($bn), 2005–2010
Table 15: Dyslipidemia Therapeutics, Major Market, France, Forecast ($bn), 2010–2018
Table 16: Dyslipidemia Therapeutics, Germany, Revenue ($bn), 2005–2010
Table 17: Dyslipidemia Therapeutics, Major Market, Germany, Forecast ($bn), 2010–2018
Table 18: Dyslipidemia Therapeutics, Italy , Revenue ($bn), 2005–2010
Table 19: Dyslipidemia Therapeutics, Major Market, Italy, Forecast ($bn), 2010–2018
Table 20: Dyslipidemia Therapeutics, Spain, Revenue ($bn), 2005–2010
Table 21: Dyslipidemia Therapeutics, Major Market, Spain, Forecast ($bn), 2010–2018
Table 22: Dyslipidemia Therapeutics, The UK, Revenue ($bn), 2005–2010
Table 23: Dyslipidemia Therapeutics, Major Market, The UK, Forecast ($bn), 2010–2018
Table 24: Dyslipidemia Therapeutics, Japan, Revenue ($bn), 2005–2010
Table 25: Dyslipidemia Therapeutics, Major Market, Japan, Forecast ($bn), 2010–2018
Table 26: Dyslipidemia Therapeutics – Phase III Pipeline, 2011
Table 27: Dyslipidemia Therapeutics – Phase II Pipeline, 2011
Table 28: Dyslipidemia Therapeutics – Phase I Pipeline, 2011
Table 29: Dyslipidemia Therapeutics – Preclinical Pipeline, 2011
Table 30: Dyslipidemia Therapeutics – Discovery Pipeline, 2011
Table 31: Dyslipidemia Therapeutics Market – Most Promising Drugs Under Clinical Development, 2011
Table 32: Dyslipidemia Therapeutics – Clinical Trials by Country, 2011
Table 33: Dyslipidemia Therapeutics, Major Markets – Clinical Trials by Phase, 2011
Table 34: Dyslipidemia Therapeutics, Major Markets, Clinical Trials by Development Status, 2011
Table 35: Dyslipidemia Therapeutics, Major Markets, Prominent Sponsors, 2011
Table 36: Dyslipidemia Therapeutics, Clinical Trials of Top Ten Companies by Phase, 2011
Table 37: GlaxoSmithKline Pipeline Products
Table 38: Merck Pipeline Products
Table 39: Pipeline Products
Table 40: Anthera Pharmaceuticals Company Pipeline Products
Table 41: Amarin Corporation, Inc Pipeline Products
Table 42: Essentialis, Inc Pipeline Products
Table 43: Aegerion Pharmaceuticals Pipeline Products
Table 44: Dyslipidemia Therapeutics – Other Companies in the Pipeline, 2011
Table 45: Dyslipidemia Therapeutics- Global Deals

1.2 List of Figures
Figure 1: Dyslipidemia Therapeutics, Global, Biosynthetic Pathway for Cholesterol
Figure 2: Dyslipidemia Therapeutics - Formation of Plaque
Figure 3: Dyslipidemia Therapeutics - Xathelasma
Figure 4: Dyslipidemia Therapeutics Market, Global, Revenue ($bn), 2005–2010
Figure 5: Dyslipidemia Therapeutics Market, Global, Forecast ($bn), 2010–2018
Figure 6: Dyslipidemia Therapeutics Market, The US, Revenue ($bn), 2005–2010
Figure 7: Dyslipidemia Therapeutics Market, The US, Forecast ($bn), 2010–2018
Figure 8: Dyslipidemia Therapeutics Market, France, Revenue ($bn), 2005–2010
Figure 9: Dyslipidemia Therapeutics Market, France, Forecast ($bn), 2010–2018
Figure 10: Dyslipidemia Therapeutics Market, Germany, Revenue ($bn), 2005–2010
Figure 11: Dyslipidemia Therapeutics Market, Germany, Forecast ($bn), 2010–2018
Figure 12: Dyslipidemia Therapeutics Market, Italy, Revenue ($bn), 2005–2010
Figure 13: Dyslipidemia Therapeutics Market, Italy, Forecast ($bn), 2010–2018
Figure 14: Dyslipidemia Therapeutics Market, Spain, Revenue ($bn), 2005–2010
Figure 15: Dyslipidemia Therapeutics Market, Spain, Forecast ($bn), 2010–2018
Figure 16: Dyslipidemia Therapeutics Market, The UK, Revenue ($bn), 2005–2010
Figure 17: Dyslipidemia Therapeutics Market, The UK, Forecast ($bn), 2010–2018
Figure 18: Dyslipidemia Therapeutics Market, Japan, Revenue ($bn), 2005–2010
Figure 19: Dyslipidemia Therapeutics Market, Japan, Forecast ($bn), 2010–2018
Figure 20: Opportunity and Unmet Need in the Dyslipidemia Therapeutics Market, 2011
Figure 21: Dyslipidemia Therapeutics, Global, Strategic Competitor Assessment, 2011
Figure 22: Dyslipidemia Therapeutics – Clinical Pipeline by Mechanism of Action, 2011
Figure 23: Dyslipidemia Therapeutics Market – Pipeline by Phase of Development, 2011
Figure 24: Technology Trends Analytics Framework, 2011
Figure 25: Dyslipidemia Therapeutics - Technology Trends Analytics Framework – Description, 2011
Figure 26: Dyslipidemia Therapeutics – Clinical Trials by Country, 2011
Figure 27: Dyslipidemia Therapeutics, Major Markets – Clinical Trials by Phase, 2011
Figure 28: Dyslipidemia Therapeutics, Major Markets, Clinical Trials by Development Status, 2010
Figure 29: Dyslipidemia Therapeutics, Overall Sponsors, 2011
Figure 30: Dyslipidemia Therapeutics, Prominent Sponsors, 2011
Figure 31: Dyslipidemia Therapeutics, Clinical Trials of Top Ten Companies by Phase, 2011
Figure 32: Dyslipidemia Therapeutics Market, Drivers and Barriers, 2011
Figure 33: Implications for Future Market Competition in the Dyslipiemia Therapeutics Market, 2011
Figure 34: Dyslipidemia Therapeutics Market – Clinical Pipeline by Company, 2011
Figure 35: Market Forecasting Model

GlobalData, the industry analysis specialist, has released its new report, “Dyslipidemia Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Dyslipidemia Therapeutics market. The report identifies the key trends shaping and driving the global Dyslipidemia Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Dyslipidemia Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Dyslipidemia Market is Competitive and Expected to Decline Due to Patent Expiries during the Forecast Period

The global dyslipidemia therapeutics market valued $26.4 billion in 2010 and is forecast to decline at a negative compound annual growth rate (CAGR) of 0.8% over the next eight years to reach $24.8 billion by 2018. The historical growth in the market was attributed to sales of statins such as Lipitor (atorvastatin calcium), Crestor (rosuvastatin calcium), Zocor (simvastatin) and Pravachol, (pravastatin) which is given as combination therapy with fenofibrates. Major blockbuster brand, Pfizer’s Lipitor patent, is set to expire in November 2011 and Astrazeneca’s Crestor will lose its patent in 2016. In addition, Lescol (fluvastatin sodium) will expire on October11, 2011 and Tricor (fenofibrate) will expire on January 25, 2011, Vyterin (ezitimibe/simavastin) and Zeita (ezitimibe) will lose their patents in Spetember, 2013, Lovaza (omega-3-acid ethyl esters) will expire on March, 26 2013 and Niaspan (nicotinic acid) will also come off patent in 2013. Livalo (pitavstatin calcium) will expire in 2015. The impending patent expiry of major approved products will have a negative impact on the market, and will reduce future growth. The entry of generics will lead to a decline in market valuation due to the low price of these drugs. Currently marketed drugs are used to reduce low density lipoprotein cholesterol (LDL-C) and increase high density lipoprotein cholesterol (HDL-C) but cannot reduce cardiovascular risk factors and the progression of atherogenecity in patients. This unmet need provides potential for new entrants with enhanced safety and efficacy profiles to enter this segment of the market. The molecules which are anticipated to enter the market during the forecast period are AMR 101, Dalcetrapib (RG 1658), Tredaptive (MK-524A), Lomitapide (AEGR-733) and Mipomersen (ISIS 301012).

Dyslipidemia Therapeutics, Global, Revenue and Market Forecast ($bn), 2005–2018

Source: GlobalData, Donna K. Arnett, PhD., et al, Twenty-Year Trends in Serum Cholesterol, Hypercholesterolemia and Cholesterol Medication Use The Minnesota Heart Survey, 1980 –1982 to 2000 –2002, American Heart Association; Robin P. Hertz., et al, Diabetes, Hypertension, and Dyslipidemia in Mexican Americans and Non-Hispanic Whites, American Journal of Preventive Medicine 2005. GlobalData, Epidemiology-based Forecasting model.

GlaxoSmithKline Plc
Merck & Co., Inc.
F. Hoffmann-La Roche
ISIS Pharmaceuticals
Anthera Pharmaceuticals
Amarin Corporation plc.
Essentialis, Inc
Aegerion Pharmaceuticals

Customers who bought this item also bought

• Global Dyslipidemia Drug Pipeline Capsule - 2012
• Epidemiology: Dyslipidemia - Undertreated and underdiagnosed pandemic
• Epidemiology: Dyslipidemia
• The Pricing and Reimbursement Environment for Metabolic Disease Therapies
• Medical Nutrition - A Global Market Overview
• Diabetes Diagnostics - Global Strategic Business Report
• Disinfectants - Global Strategic Business Report
• Overactive Bladder (OAB) Therapeutics - Global Strategic Business Report
• Market and Product Forecasts: Antidyslipidemics - Set for the impact of generic Lipitor
• Molecular Diagnostics - Global Strategic Business Report